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The feasibility of ex vivo blood production is limited by both biological and engineering challenges. From
an engineering perspective, these challenges include the significant volumes required to generate even a
single unit of a blood product, as well as the correspondingly high protein consumption required for such
large volume cultures. Membrane bioreactors, such as hollow fiber bioreactors (HFBRs), enable cell densities
approximately 100-fold greater than traditional culture systems and therefore may enable a significant reduc-
tion in culture working volumes. As cultured cells, and larger molecules, are retained within a fraction of
the system volume, via a semipermeable membrane it may be possible to reduce protein consumption by
limiting supplementation to only this fraction. Typically, HFBRs are complex perfusion systems having total
volumes incompatible with bench scale screening and optimization of stem cell-based cultures. In this article
we describe the use of a simplified HFBR system to assess the feasibility of this technology to produce
blood products from umbilical cord blood-derived CD34+ hematopoietic stem progenitor cells (HSPCs).
Unlike conventional HFBR systems used for protein manufacture, where cells are cultured in the extracapil-
lary space, we have cultured cells in the intracapillary space, which is likely more compatible with the large-
scale production of blood cell suspension cultures. Using this platform we direct HSPCs down the myeloid
lineage, while targeting a 100-fold increase in cell density and the use of protein-free bulk medium. Our
results demonstrate the potential of this system to deliver high cell densities, even in the absence of protein
supplementation of the bulk medium.
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INTRODUCTION practice” methods such that clinically relevant cell
numbers could be generated. A key conclusion was that
generating the necessary cell numbers, utilizing currentRed blood cell and platelet transfusions are routine
life-saving procedures in medicine. While the relative best practice cell densities and expansion protocols,
would require culture volumes that preclude the feasibil-ease of harvest and storage of these cell subsets enable
this process, an adequate supply of suitable donor mate- ity of either RBC or platelet manufacture.
Our general inability to replicate the cell density andrial remains problematic. The production of ex vivo-
generated transfusible blood products, or Blood Pharm- efficiency achieved within the human body is perhaps
most strikingly appreciated by considering current meth-ing, remains one of the most promising, as well as per-
haps one of the most distant, deliverables of current cell ods for RBC production. Utilizing the protocols devel-
oped by Giarratana et al. (10), producing a single unitexpansion technologies. The current technical limita-
tions are both biological and engineering in nature. We of RBCs (1012 cells) would require 660 L of medium
(assuming a cell density of 3 × 106 cells/ml) or approxi-recently reviewed the individual challenges associated
with production of red blood cells (RBCs), platelets, and mately 9,500 traditional laboratory T175 flasks (25). In
contrast to RBC manufacture, the ex vivo production ofneutrophils (25). The most promising culture methods
for producing each cell product were reviewed and criti- neutrophils for temporary immune support may be more
feasible given the reduced necessary cell number (1010cally analyzed for the feasibility of scaling these “best
Received December 1, 2010; final acceptance June 30, 2011. Online prepub date: March 8, 2012.
Address correspondence to Dr. Michael R. Doran, B.Sc., B.Eng., Ph.D., Stem Cell Therapies Laboratory, Institute of Health and Biomedical
Innovation, Queensland University of Technology, Brisbane, QueenslandAustralia 4059. Tel: +61 (0)7 3138 0311; Fax: +61 (0)7 3138 6030;
E-mail: michael.doran@qut.edu.au
1235
1236 DORAN ET AL.
cells/dose) (27), as well as the economic motivation to as a medium reservoir. While intracapillary culture is
uncommon, there are potential benefits in that the plugoffset the significant cost of hospitalizing neutropenic
patients (25). In either case, one of the critical engineer- flow nature of fluid through the capillaries enables
homogenous seeding as well as easy harvest. Previousing requirements is the development of high-density cell
culture strategies that reduce the working volume of studies have identified challenges in harvesting cells
from extracapillary cultures (24). In addition, the main-blood product cultures, and thus the relative cost of pro-
ducing such cell subsets for clinical use. tenance of HSPCs within fibers overcomes problems
associated with cell settling in the extracapillary vol-In a previous article we outlined the development and
use of a membrane microbioreactor designed to enable ume—a significant concern with nonadherent cell types.
In the HFBR described herein, the HSPCs are culturedthe culture of cord blood-derived hematopoietic stem
progenitor cells (HSPCs) at densities 100-fold greater in the intracapillary space with the fibers simply sub-
merged in a static medium reservoir that supplies lowthan those traditionally realized in a static culture flask
(7). This microbioreactor system enabled high cell den- molecular weight nutrients such as oxygen, glucose, and
amino acids. HSPCs, and high molecular weightsity cultures to be achieved by enhancing mass transport
through sandwiching the cells between a gas permeable medium supplements, are loaded into the intracapillary
volume, while the bulk extracapillary reservoir (99% ofmembrane and a semipermeable membrane that permit-
ted the exchange of medium components, less than 10 the system volume) contains protein-free medium. The
10-kDa molecular weight cut-off (MWCO) of thekDa in size, from a bulk medium reservoir. The primary
objective of this previous work was to evaluate the feasi- CuprophanTM membrane (Membrana, Germany) retains
high molecular weight supplements, such as cytokines,bility and impact of high cell density culture on HSPC
expansion. Our results indicated that, over the culture within the fiber lumen, thus preventing their dilution
into the bulk medium.durations assessed, HSPC expansion was not compro-
mised and could in fact be enhanced, in some cases, In this study we use this simplified HFBR system to
evaluate the potential of the hollow fiber geometry forwhen the local cell density was increased 100-fold in
the bioreactor. While we feel that this device represents use in high-density expansion of HSPCs. In these exper-
iments HSPCs are directed down the myeloid lineage,a suitable tool with which to further optimize culture
conditions for high cell density production of specific which is perhaps a logical starting place as neutrophils,
as a blood product, are most likely to be clinically avail-blood cell subsets, we acknowledge that its micronature
does not fully address the engineering scaling challenges able in the near future (25,26).
that currently hinder blood product production. It is
MATERIALS AND METHODSlikely that scaling will favor geometries such as those
Fabrication of the HFBRprovided by hollow fiber bioreactors (HFBRs), rather
than simple sandwich designs such as that described in It is our opinion that the complexities and volumes of
traditional HFBR systems limit “bench-level” screening,our previous work.
While there are many HFBRs on the market, their and are therefore not appropriate for the first pass evalu-
ation of the expansion of HSPCs in a hollow fiber-basedvolumes and system complexities tend to be too great
for the “screening level” assessment and optimization of system. In order to minimize complexity, the hollow
fiber system shown in Figure 1 was fabricated. Cupro-high-density HSPC cultures, where input cells are lim-
ited and growth factor supplements are costly. When phanTM (Membrana, Germany) was potted in polydi-
methylsiloxane (PDMS, Sylgard 184, Dow Corning),hollow fiber dialyzers are utilized in the culture of cells
for protein production, cells are cultured on the extra- where 5-ml syringes (Terumo Corp, Philippines) were
used both as a mold for potting and as the intracapillarycapillary side or on the intracapillary side if the cell sus-
pension is being recirculated as in an alternating header or manifold. Each fiber bundle contained 187
fibers, having a length of 17 cm and inner diameters oftangential flow (ATF) device (9). In either case pumps
are required to drive perfusion. 200 µm, providing a total intracapillary volume of 1 ml.
Fiber bundles were prepared by first dipping the endsIn the first demonstrated HFBR, Knazek et al. cul-
tured cells in the extracapillary space while perfusing (terminal 5 mm) of the fibers in PDMS and curing the
PDMS at 80°C for 20 min. This step was found to bemedium through the intracapillary space (18). The
geometry of hollow fiber systems is such that the intra- necessary to prevent further flow of PDMS into chan-
nels in subsequent stages of the fiber bundle preparation.capillary volume is always less than the extracapillary
volume. Generally cells are cultured in the extracapillary A 5-ml syringe body was then used as a mold to cast
the fibers in a PDMS plug. The terminal ends of thespace, and this obligates perfusion through the intracapi-
llary space, as relative to the extracapillary space there bundles were placed into the syringe body molds and
then backfilled with approximately 5 ml of liquidis minimal volume in the intracapillary space to function
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restoration of mass transport properties. The extracapil-
lary volume was then drained to allow clear visualiza-
tion of the fibers. Fluid volumes were introduced into
the intracapillary side using a syringe and needle via a
three-way valve and syringe bung as shown in Figure 2.
A sterile syringe/needle was used every time and the
syringe bung was sterilized before each addition using
70% ethanol. Fluid exited the opposite fiber bundle
header into a closed reservoir. Prior to the addition of
cells to the HFBR we purged the fibers with Stemline II
medium (Sigma-Aldrich, St. Louis, MO). This purge
was done purposefully and continuously until any air
bubbles remaining in the fiber bundle were eliminated.
Cell and Medium Preparation
Umbilical cord blood from full-term deliveries was
Figure 1. The image shows a static hollow fiber bioreactor. A obtained with informed consent, from both the Royal
bundle of hollow fibers is contained in a standard T75 flask. Brisbane and Women’s Hospital Human Research Eth-Cells are loaded into the fiber lumens from the syringe head- ics Committee and the University of Queensland Medi-ers, while the fibers themselves are bathed in medium con-
cal Research Ethics Committee. Mononuclear cells weretained within the flask.
isolated by centrifugation on Ficoll-Paque (Amersham
Biosciences, Uppsala, Sweden) and enriched for CD34+
cells using Mini-MACS columns (Miltenyi Biotech,
Bergisch Gladbach, Germany). We found the cell popu-
PDMS. PDMS was cured at 80°C for 20 min. The cast lations to be 95% CD34+ after two passes through the
bundles were then cut from the syringe molds and a magnetic associated cell sorting (MACS) column.
razor blade used to cleanly cut the majority of the cast At least 2 bioreactors and 16 control cultures were
PDMS and fibers from the bundle leaving an approxi- initiated in each study, thus requiring in excess of 106
mate 1.5 cm PDMS cast fiber bundle. The terminal ends input cells. To meet this requirement, and to mitigate
of the bundles were then placed into fresh 5-ml syringe the risks associated with biological variability, all cul-
bodies that had been cut at the 1.5-ml mark. This small tures were initiated with cells from two or more unique
length of syringe body then became the header, with the cord blood isolations. These cells were then further
male luer lock being the entrance/exit into the fiber bun-
dle. The PDMS fiber bundle plug was pushed deep into
the syringe body in order to minimize the header vol-
ume. While the PDMS plug formed a tight well-fitted
seal with the syringe body, this seal was further
enhanced by placing a small volume (0.5 ml) of liquid
PDMS into the back end of the syringe header. This
additional seal was then cured at 80°C for 20 min. The
fiber bundles were each mounted into individual T75
flasks (Becton, Dickinson and Company, Franklin
Lakes, NJ). At the tail end of each flask 11-mm-diame-
ter holes were drilled through the polystyrene and the
syringe header fixed in place using silicone sealant (Sel-
leys, Auckland, NZ). The finished bioreactor systems
were gas sterilized using ethylene oxide and then per-
mitted to degas for at least 1 month.
Preparation of the HFBR Figure 2. Fiber bundle header and inlet valve. Medium and
cells are injected into the system through the syringe port, thusBefore use in culture both the intracapillary and facilitating sterile fluid exchange. Following cell loading the
extracapillary volume of the bioreactor were rinsed thor- three-way valve was used to isolate the fiber bundle and thus
oughly with phosphate-buffered saline (PBS). The fibers to prevent axial medium movement over the duration of the
culture.were left wet for at least 30 min to ensure hydration and
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expanded in flask cultures for 3 days to confirm cell CD11b-phycoerythrin (PE; Miltenyi Biotech) as per
manufacturer’s instructions.viability and to ensure adequate cell number at day 0
of the bioreactor study. This was necessary to ensure
Statistical Analysisstatistical viability where the input cell number into each
SPSS 17.0 (SPSS Inc., Chicago, IL) was used forexperiment was greater than 5 million cells, and we gen-
one-way analysis of variance (ANOVA) with Tukeyerally obtain fewer than 500,000 CD34+ cells from each
post hoc tests to assess statistical significance, whichcord harvest. In clinical applications where larger har-
was defined as p < 0.05. Number of replicates is statedvests are possible and statistical replicates are not neces-
in the figure captions.sary, this step could be eliminated, making the process
a single expansion step in the bioreactor starting at day
RESULTS AND DISCUSSION0. In initial flask cultures the cells were suspended at
Mass Transport50,000 cells/ml in Stemline II medium supplemented
with 100 ng/ml each of stem cell factor (SCF, Stemgen; The use of the hollow fiber geometry in high cell
Amgen, Sydney, Australia), thrombopoietin peptide density bioreactor systems is routine in protein produc-
(TPO; AusPep, Parkville, Australia) (4), granulocyte tion applications. However, as this particular system and
colony-stimulating factor (GCSF, Neupogen; Amgen), application is unique we used a shell balance mass trans-
and 100 U/ml penicillin and 100 mg/ml streptomycin port model to predict the local concentration of oxygen
[1% penicillin streptomycin (PS); Gibco-Invitrogen, and glucose in a fiber packed with HSPCs. Assuming
Carlsbad, CA]. that the concentration of either metabolite is at a uniform
Following 3 days of preculture, cells were harvested, concentration on the outside of the fiber, the analytical
concentrated by centrifugation (300 × g for 5 min) and solution to the shell balance is:
then resuspended at 106 cells/ml in Stemline II medium
supplemented with 10,000 ng/ml SCF, TPO, GCSF, 1% Cr = CR −
k
4D
[R2 − r2]
penicillin streptomycin, and 100 µl/1 ml (1:10) of insu-
lin-transferrin-selenium-X (ITS; Gibco-Invitrogen) (7). where C is the metabolite concentration, R is the fiber
Three milliliters of this cell suspension was used to fill radius, k is specific metabolite uptake rate, and D is the
the intracapillary volume of each reactor, such that we diffusion coefficient for that metabolite. The values for
could be confident that the 1-ml fiber volume had been these constants are provided in Table 1 and a plot of the
effectively exchanged with this inoculation cocktail. metabolite profiles is shown in Figure 3. Note that we
Great care was taken not to introduce bubbles into the were not able to find a diffusion constant for oxygen
fibers. The extracapillary volume of the flask was then through CuprophanTM membrane. The known value for
filled with 100 ml of RPMI (Rosswell Park Memorial glucose diffusion through CuprophanTM was utilized as
Institute) medium supplemented with 1% penicillin a conservative estimate, given that oxygen transport
streptomycin. through the membrane should be more efficient than
Control cultures were made from the addition of 10 glucose. The metabolite profiles shown in Figure 3 indi-
µl of the intracapillary inoculum into either 990 µl of cate that a cell density of 109 cells/ml, 10-fold greater
protein-free RPMI or Stemline II. In doing so the ratios than targeted in this study, is required to reduce the oxy-
of protein in the RPMI control and in the HFBR were gen concentration in the center of the fiber to zero. If a
equal. The seeding density of these cultures was 10,000 cell density of 108 cells/ml is used, the model predicts a
cells/ml with growth factor concentrations of 100 ng/ml. core oxygen concentration of 0.018 mM. Again, at 109
Cultures were then maintained for 7 days in 37°C, cells/ml the glucose concentration would be approxi-
5% CO2 incubators where the atmosphere contained mately 11.2 mM at the core of the fiber. While this sim-
2% oxygen. ple model does not account for gradients through the
Cell Characterization
Table 1. Mass Transport Model ConstantsCells harvested from bioreactors or from well plate
cultures were enumerated, and then characterized by Constant Value Reference
flow cytometry. Cell counts were performed using a Cell
HSC glucose uptake 3.33 × 10−17 mol/cell(s) 3Lab Quanta SC (Beckman Coulter, Fullerton, CA). Flow
HSC oxygen uptake 1.66 × 10−17 mol/cell(s) 6cytometry (LSR Becton Dickinson, Franklin Lakes, NJ)
DCuprophan-Glucose 1.22 × 10−4 cm2/s 12was performed to identify the proportion of the cell pop-
DCuprophan-Oxygen 1.22 × 10−4 cm2/s 1ulation that had progressed down the myeloid lineage.
DTissue-Glucose 5.00 × 10−6 cm2/s 16The cells were labeled with monoclonal mouse anti-
DTissue-Oxygen 2.00 × 10−5 cm2/s 2human CD15-fluorescein isothiocyanate (FITC; Mil- Cell density 109 cells/ml
tenyi Biotech) and monoclonal mouse anti-human
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Figure 3. Mass transport model through cell fibers packed with cells at a density of 109 cells/ml.
Assuming an extracapillary oxygen concentration of 0.02 mM (approximately equivalent to 2% O2
atmosphere), the core fiber oxygen concentration would drop to 0 mM if a cell density 10-fold
greater than intended was achieved. Glucose concentration would drop to approximately 11.2 mM
or still in excess of twofold greater than what would be considered a low blood serum concentra-
tion. This result indicates that metabolite supply should not be limited in this system.
static volume of the bulk medium reservoir, it does uti- system (7). Notably the membrane will exclude the pas-
sage of proteins having a molecular weight greater thanlize a cell density of 109 cells/ml, which is 10-fold
greater than the maximum target cell density for this 10 kDa such as albumin, transferrin, SCF, TPO, and
GCSF. If a membrane having a molecular weight cut-system. It should be noted that the fibers are neutral to
slightly buoyant in the bulk medium and thus the fibers off of less than 5.5 kDa was selected (such a cellulose-
based fiber membrane is not, to our knowledge, com-float off the bottom of the flask near the air–liquid inter-
face, but not above. The selection of 2% oxygen was mercially available) then all supplemented proteins,
including insulin, would be retained in the fiber.based on our previous work with HSPC expansion in
bioreactors where culture performance was enhanced at
Cell Expansion and Analysislow oxygen concentrations (7). Further, a reduced oxy-
gen atmosphere was thought to be a logical selection as All cultures were inoculated with cells suspended at
106 cells/ml in StemLine II medium containing ITS andthe proposed reduction in medium protein content (spe-
cifically albumin) would make cultures more sensitive growth factors. The cell inoculation volume was equiva-
lent to 1% of the total culture volume. The inoculationto oxidative stress (8).
Note that the extracapillary medium in the HFBR is was used to initiate cultures in either well plates con-
taining StemLine II medium, or RPMI medium with noadded without protein supplement, but that some com-
ponents of the Stemline II and ITS supplement will pass protein supplement, or into the HFBR where the extra-
capillary medium contained RPMI with no protein sup-through the fiber and be diluted into the bulk medium.
For example, the selenium and insulin in the ITS supple- plement. Thus, on a percentage basis the protein
contents in the RPMI well plate control and in thement would be expected to be diluted into the bulk
medium. In this case the ITS supplement would be HFBR were equivalent.
Images of the HSPC-derived cell culture within thediluted to 1:1,000 of the stock concentration (still within
accepted working range), resulting in a final concentra- fiber lumens are shown in Figure 4. These images
immediately demonstrate the successful expansion oftion equivalent to that in control cultures. In our previ-
ous work we demonstrated that this concentration of ITS the cells in this device, while also revealing the hetero-
geneous distribution of the cells just prior to harvest.was sufficient to expand HSPC cultures in a membrane
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Figure 4. (A) Fibers loaded with cells at day 0. Cells are reasonably uniformly dispersed. (B) Cells in fibers at day 7. Some
sections of the fibers are packed with cells, while other sections appear to be void of cells over portions of the fiber length. The
closed arrow points to a fiber filled with cells, while the open arrow points to adjacent fiber devoid of cells over the length shown
in the image.
This distribution and the potential implications are dis- hematopoietic cells in each of the culture systems. Our
results indicate that the preferred expansion environmentcussed later.
Actual cell expansion was determined by direct coun- was the well plate using StemLine II medium (approxi-
mately 30-fold expansion), with statistically equivalentting of the cell product generated from each of the cul-
tures. Figure 5 shows the relative fold expansion of results obtained in the bioreactor. In contrast, cultures
Figure 5. The plot displays the fold expansion of cells in each culture system. The upper and
lower panels provide example outcomes from two independent experiments performed on two
separate occasions. Fold expansion in well plate: RPMI (no protein) cultures is statistically
(ANOVA, p < 0.01) less than that observed in either StemLine II or Bioreactor cultures. Each of
the four bioreactor, in the two experiments, was sampled four times (technical replicates), while
each well plate condition has been replicated four times and sampled two times (two technical
replicates). Bars indicate averages, while error bars represent 1 SD.
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maintained in well plates with RPMI medium performed In the experiments presented here the total cell
expansion in the bioreactor system was approximatelypoorly. The total system relative protein and cell content
was identical in the RPMI well plate cultures and the 30-fold (Fig. 5), resulting in a cell density in the fibers
of approximately 3 × 107 cells/ml. In contrast, our staticbioreactor cultures, yet the bioreactor cultures performed
significantly better. This initial result is significant, as it StemLine II cultures reached a cell density of approxi-
mately 3 × 105 cells/ml. While a cell density of 3 × 107indicates that by sequestering the small quantity of pro-
tein into the fiber volume (1% of the system volume), it cells/ml is an impressive 10-fold greater than typical
static culture confluence, the total culture cell numberis possible to achieve significantly greater cell expansion
than is possible when this same quantity of protein is and fiber volume space should enable a further two more
population doublings before reaching confluence in thediluted through the total culture volume as occurs in the
RPMI well pate control. If we assume that the consump- bioreactor system. These results demonstrate that this
culture methodology is viable. Future work will seek totion of medium metabolites is similar in each system
then the total medium consumption, no matter the cul- extend the culture period and range of expansion by tri-
aling lower cell seeding densities and perhaps evaluatingture methodology, will be similar. However, if it is pos-
sible, as shown here, to successfully generate a cell densities greater than 108 cells/ml. We speculate that for
such high densities to be achieved, and to avoid varia-product where 99% of the medium utilized in the system
is protein-free then this savings may justify the added tion in results, the lumen contents will likely require
mixing. In Figure 4 we noted that there was heterogene-complexity of membrane bioreactor systems, particu-
larly as culture volumes approach scales such as 660 L ity in the cell distribution at harvest. There are a number
of factors that may have contributed to this. Our assess-per unit of cell product generated (10). While our exper-
iments and discussion focus on the inclusion or exclu- ment of the bioreactor at time zero eliminates inconsis-
tency in cell seeding as being the source. This impliession of protein from the bulk medium, there may be the
potential to replace albumin in the bulk medium with that the heterogeneous distribution is the result of some
phenomenon occurring during the expansion process.other less expensive large molecules such as Pluronic
F68 (15). Such supplementation has been used success- This may include the innate varied expansion potential
of individual cells (28), or the indirect effects of localfully in the culture of immortal cell lines, but has not
achieved similar success or popularity in the culture of cell–cell signaling networks or cytokine supply. It is
reasonable to expect that signaling networks would existHSPCs. However, the use of semipermeable membranes
may enable advantageous exploitation of such protein- (17), and that due to the fiber geometry individual popu-
lation networks could be distinct and isolated from otherfree alternative in HSPC culture.
The maturation of cells was assessed via flow cytom- networks, including those spatially separated in the same
fiber. To demonstrate that such a claim is rational, weetry. Figure 6A–C shows the flow cytometry scatter
plots of cells harvested from each culture system and consider the characteristic diffusion time of a 20-kDa
signal molecule (this is comparable to recombinantstained for myeloid markers CD11b and CD15. We only
screened these cultures for myeloid cells, as the selected human G-CSF which is 18.8 kDa and/or recombinant
human SCF monomer which is 18.6 kDa; R&D Sys-growth factor cocktailed should effectively promote
myeloid differentiation. In previous work we have tems, Minneapolis, MN) over a distance of 1 cm. First,
a molecule of this size would be excluded from passingshown that, over time, this combination of factors results
in a virtually pure population of postmitotic neutrophils through the fiber dialysis membrane (10 kDa MWCO)
and therefore could not influence cells outside that same(26). The scatter plots (Fig. 6) indicate a similar level of
maturation in both the StemLine well plate cultures and fiber. For a hypothetical signal molecule of 20 kDa the
diffusion coefficient is estimated to be 7.44 × 10−7 cm2/in the bioreactor cultures. In contrast, the scatter plot of
the RPMI (protein-free) culture indicates that less matu- s using a relation developed by Preston and Comper
[Equation 1 (23)]:ration has occurred in these cultures. This is also shown
quantitatively in Figure 6D, revealing that the StemLine D = 1.76 × 10−8(MW)−0.552 (1)
cultures are in fact the most mature of the three culture
where D is the diffusion coefficient (m2/s) and MW
conditions. Only the proportion of CD14+/CD15+ popu- is the molecular weight. Using Equation 2, it is possiblelations are similar between the bioreactor and StemLine
to estimate the time when approximately 90% of theII cultures, with maturation in the RPMI (no protein)
transient diffusion would have occurred over the 1-cm
cultures being significantly delayed. In HSPC cultures length (21):differentiation is generally coupled with expansion, so
Tdiff = L2/D (2)we would expect that in RPMI cultures, where reduced
expansion was observed (Fig. 5), that maturation would where Tdiff is the characteristic diffusion time, L is the
diffusion distance, and D is the diffusion coefficient.also be delayed (Fig. 6).
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Figure 6. Flow cytometry scatter plots of cells harvested from each culture system. (A) StemLine
well plate cultures, (B) RPMI (no protein) well plate cultures, and (C) is bioreactor cultures. The
scatter data suggest a similar level of maturation in the StemLine and bioreactor cultures, with less
maturation in the RPMI (no protein) cultures. (D) Flow cytometry data demonstrating the relative
proportion of maturing myeloid cells in each culture system. Plotted bioreactor data are generated
from two separate bioreactors, each with two technical replicates (n = 4). Plotted well culture data
are generated from n ≥ 3 independent cultures (ANOVA, *p ≤ 0.05, **p ≤ 0.01, each sample is of
10,000 events). Bars represent means, while error bars represent 1 SD.
For this system, the characteristic diffusion time over the fibers were initially loaded uniformly that distinct
microenvironments would develop, further exaggeratinga 1-cm length is approximately 375 h. The accuracy of
this estimate is a function of both the selected empirical the heterogeneity that exists in the CD34+-selected
HSPC population (28). Prolonged diffusion times couldrelation for diffusion coefficient estimation and the
generic nature of the time constant relation, which does generate scenarios where rapid cell expansion in one
portion of a fiber might deplete local growth factor sup-not account specifically for hollow fiber geometry.
While generic in nature, this estimate is similar to that ply, despite the fact that adjacent fiber lengths might
be void of cells and therefore remain rich in availablegenerated using other relations (21). Critically these esti-
mates put in perspective the qualitative isolation that growth factors.
would likely exist between two cell clusters separated
Probable Future Developmentsby 1 cm in the same fiber. As the fibers in this bioreactor
system are 17 cm in length, it is quite reasonable to While we are able to present promising results
regarding the high-density expansion of myeloid pro-assume that over the length of a single fiber a number
of distinct and isolated microenvironments could genitors, the described observation provides opportunity
for future improvement. It is likely that in order to fullydevelop. As a result, it is logical to expect that even if
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exploit the potential of HSPCs in this culture system, ligands as used in the two recent clinical trials (5,20).
As HFBR have been in use for decades, it is likely thatand to consistently generate a uniform cell product,
some sort of periodic mixing will have to be introduced. hollow fiber-based expansion protocols could be rapidly
scaled and even integrated into existing platforms.While the culture of cells inside the fiber lumen is virtu-
ally unreported (11), culture in the extracapillary space
is very common and in such systems mixing of the CONCLUSION
extracapillary cell volume has been identified as a nec- Neutrophil transfusion for temporary immune support
essary step in some cases (22). Such a mixing protocol
remains uncommon due to the challenge of obtaining
would likely involve displacing the cells from the fiber
sufficient functional donor cells, coupled with difficulty
lumen, mixing the contents, and then returning the in storing this cell subset (14). Blood Pharming, or the
mixed contents back into the fibers. To our knowledge in vitro production of blood products, could potentially
such a system where cells are cultured on the lumen side
overcome these limitations, providing an immediate
of the bioreactor, and mixed periodically, has not been
source of pathogen-free donor material. In general, the
reported. Such action would likely reduce potential het-
critical engineering limitation currently preventing blood
erogeneity in the soluble environment and better utilize product production is the massive volumes required to
factors that might otherwise never physically come into generate even a single unit of cell product. In this article
contact with cells in the fiber. Such a system could also
we contrast blood cell expansion, starting with CD34+
be designed to facilitate sampling of the cell population
cord blood cells, in an optimized commercial medium,
and the temporal exchange of the cytokine cocktail. The in our HFBR and in a traditional culture system where
inability to sample cell populations in a HFBR system, the total protein content is equivalent to that of the
such as the one described here, could be consider a sig- HFBR system. Our results demonstrate that while the
nificant limitation because it compromises real-time cul-
optimized commercial medium in a conventional static
ture optimization and quality control. Incorporating the
culture performs best, the HFBR system’s performance
proposed design modifications would likely improve the
was virtually equivalent in terms of both total cell
output and reliability of the HFBR in stem cell culture,
expansion and maturation. This result is promising as
which, when coupled with its ability to enable cell high- the HFBR system utilizes significantly less protein and
density expansion with less protein consumption, might
achieves an approximate 100-fold greater cell density.
well make it a preferred culture system for large-scale By contrast, in traditional well plate cultures, where the
production of blood products. total protein content was similar to that in the HFRB,
cell expansion and maturation was significantly delayed.Further Applications
These results suggest that if the protein content in the
For many decades considerable resources have been
culture system can be sequestered into the same volume
dedicated to achieving true self-renewal of HSPCs in faction as the cells, then it may not be necessary to sup-
vitro, with the understanding that provision of a greater plement the remaining medium fraction to achieve
HSPC dose would enhance cord blood transplant out-
acceptable expansion outcomes. We believe this work
comes (13,19). While achieving extensive true HSPC
represents an important step towards Blood Pharming by
self-renewal in vitro has proven exceedingly challeng-
achieving both an increase in cell densities and a reduc-
ing, and transplant trials based on the provision of these tion in protein consumption.
expanded HSPCs provided minimal efficacy, the provi-
ACKNOWLEDGMENTS: The authors would like to thanksion of progenitor cell populations, providing short-term
Inner Wheel Australia and the Queensland University of Tech-engraftment and immune support, has proven to be ben-
nology’s Vice Chancellor’s Fellowship Scheme. The authors
eficial (5,20). These results may indicate a shift in declare no conflict of interest.
strategy, acknowledging that cotransplantation of an
unmanipulated cord blood HSPC population with a tran- REFERENCES
siently supportive blood product may provide the
1. Baltz, J. M.; Biggers, J. D. Oxygen-transport to embryosrequired efficacy to make this therapy suitable for adult in microdrop cultures. Mol. Reprod. Dev. 28(4):351–patients. As such strategies evolve, it is likely that clini- 355; 1991.
cians will request greater doses of support cells in order 2. Chow, D. C.; Wenning, L. A.; Miller, W. M.; Papoutsakis,
E. T. Modeling pO(2) distributions in the bone marrowto maximize efficacy, thus creating a further need for bior-
hematopoietic compartment. I. Krogh’s model. Biophys.eactor systems capable of producing large cell numbers
J. 81(2):675–684; 2001.efficiently. The system outlined in this article may be a 3. Collins, P. C.; Nielsen, L. K.; Wong, C. K.; Papoutsakis,
suitable platform as the hollow fiber system, which pro- E. T.; Miller, W. M. Real-time method for determining
vides a high surface area for mass transport, could also the colony-forming cell content of human hematopoietic
cell cultures. Biotechnol. Bioeng. 55(4):693–700; 1997.be used to for the attachment of support cells or bound
1244 DORAN ET AL.
4. Cwirla, S. E.; Balasubramanian, P.; Duffin, D. J.; Wags- growth in a fully defined protein-free and cholesterol-free
culture-medium. Cytotechnology 17(3):203–211; 1995.trom, C. R.; Gates, C. M.; Singer, S. C.; Davis, A. M.;
Tansik, R. L.; Mattheakis, L. C.; Boytos, C. M.; Schatz, 16. Kirkpatrick, J. P.; Brizel, D. M.; Dewhirst, M. W. A math-
ematical model of tumor oxygen and glucose mass trans-P. J.; Baccanari, D. P.; Wrighton, N. C.; Barrett, R. W.;
Dower, W. J. Peptide agonist of the thrombopoietin recep- port and metabolism with complex reaction kinetics.
Radiat. Res. 159(3):336–344; 2003.tor as potent as the natural cytokine. Science 276(5319):
1696–1699; 1997. 17. Kirouac, D. C.; Madlambayan, G. J.; Yu, M.; Sykes,
E. A.; Ito, C.; Zandstra, P. W. Cell–cell interaction net-5. Delaney, C.; Heimfeld, S.; Brashem-Stein, C.; Voorhies,
H.; Manger, R. L.; Bernstein, I. D. Notch-mediated expan- works regulate blood stem and progenitor cell fate. Mol.
Syst. Biol. 5:293; 2009.sion of human cord blood progenitor cells capable of rapid
myeloid reconstitution. Nat. Med. 16(2):232–236; 2010. 18. Knazek, R. A.; Gullino, P. M.; Kohler, P. O.; Dedrick,
R. L. Cell culture on artificial capillaries: An approach to6. De Leon, A.; Mayani, H.; Ramirez, O. T. Design, charac-
terization and application of a minibioreactor for the cul- tissue growth in vitro. Science 178(56):65–66; 1972.
19. Koestenbauer, S.; Zisch, A.; Dohr, G.; Zech, N. H. Proto-ture of human hematopoietic cells under controlled
conditions. Cytotechnology 28(1–3):127–138; 1998. cols for hematopoietic stem cell expansion from umbilical
cord blood. Cell Transplant. 18(10):1059–1068; 2009.7. Doran, M. R.; Markway, B. D.; Clark, A.; Athanasas-
Platsis, S.; Brooke, G.; Atkinson, K.; Nielsen, L. K.; 20. Mesoblast_Media_Release. Successful bone marrow regen-
eration in cancer patients using cord blood expanded byCooper-White, J. J. Membrane bioreactors enhance micro-
environmental conditioning and tissue development. proprietary stem cells. Melbourne, Australia: Mesoblast
Ltd; 2009.Tissue Eng. Part C Methods 16(3):407–415; 2010.
8. Francis, G. L. Albumin and mammalian cell culture: 21. Palsson, B. O.; Bhatia, S. N. Tissue engineering. Upper
Saddle River, NJ: Pearson Prentice Hall; 2004.Implications for biotechnology applications. Cytotechnology
62(1):1–16; 2010. 22. Piret, J. M.; Cooney, C. L. Mammalian cell and protein
distributions in ultrafiltration hollow fiber bioreactors.9. Furey, J. Continuous cell culture using the ATF system.
Genet. Eng. News 20(10):52–53; 2000. Biotechnol. Bioeng. 36(9):902–910; 1990.
23. Preston, B. N.; Comper, W. D. Diffusion of dextrans at10. Giarratana, M. C.; Kobari, L.; Lapillonne, H.; Chalmers,
D.; Kiger, L.; Cynober, T.; Marden, M. C.; Wajcman, H.; intermediate concentrations. J. Chem. Soc. Faraday Trans.
178:1209–1221; 1982.Douay, L. Ex vivo generation of fully mature human red
blood cells from hematopoietic stem cells. Nat. Biotechnol. 24. Sardonini, C. A.; Wu, Y. J. Expansion and differentiation
of human hematopoietic-cells from static cultures through23(1):69–74; 2005.
11. Gramer, M. J.; Poeschl, D. M. Screening tool for hollow- small-scale bioreactors. Biotechnol. Progr. 9(2):131–137;
1993.fiber bioreactor process development. Biotechnol. Progr.
14(2):203–209; 1998. 25. Timmins, N. E.; Nielsen, L. K. Blood cell manufacture:
Current methods and future challenges. Trends Biotechnol.12. Hinrichs, W. L. J.; tenHoopen, H. W. M.; Engbers, G. H. M.;
Feijen, J. In vitro evaluation of heparinized Cuprophan 27(7):415–422; 2009.
26. Timmins, N. E.; Palfreyman, E.; Marturana, F.; Dietmair,hemodialysis membranes. J. Biomed. Mater. Res. 35(4):
443–450; 1997. S.; Luikenga, S.; Lopez, G.; Fung, Y. L.; Minchinton, R.;
Nielsen, L. K. Clinical scale ex vivo manufacture of neu-13. Huang, X.; Pierce, L. J.; Cobine, P. A.; Winge, D. R.;
Spangrude, G. J. Copper modulates the differentiation of trophils from hematopoietic progenitor cells. Biotechnol.
Bioeng. 104(4):832–840; 2009.mouse hematopoietic progenitor cells in culture. Cell
Transplant. 18(8):887–897; 2009. 27. Vamvakas, E. C.; Pineda, A. A. Determinants of the effi-
cacy of prophylactic granulocyte transfusions: A meta-14. Hubel, K.; Dale, D. C.; Engert, A.; Liles, W. C. Current
status of granulocyte (neutrophil) transfusion therapy for analysis. J. Clin. Apheresis 12(2):74–81; 1997.
28. Wognum, A. W.; Eaves, A. C.; Thomas, T. E. Identifica-infectious diseases. J. Infect. Dis. 183(2):321–328; 2001.
15. Keen, M. J.; Steward, T. W. Adaptation of cholesterol- tion and isolation of hematopoietic stem cells. Arch. Med.
Res. 34(6):461–475; 2003.requiring Ns0 mouse myeloma cells to high-density
